Specific effects of bortezomib against experimental malignant pleural effusion: A preclinical study

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  Psallidas, Ioannis ^a,b   Karabela, Sophia P ^a   Moschos, Charalampos ^a,b   Sherrill, Taylor P ^c   Kollintza, Androniki ^a   Magkouta, Sophia ^a   Theodoropoulou, Panagiota ^a   Roussos, Charis ^a   Blackwell, Timothy S ^c   Kalomenidis, Ioannis ^a,b   Stathopoulos, Georgios T ^a,c,d  

^a UNIVERSITY OF ATHENS   (Greece)

^b NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PATRAS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; AUTACOID; BORONIC ACID DERIVATIVE; PROTEASOME; PYRAZINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; GENE ACTIVATION; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSCRIPTION; GROWTH INHIBITION; LEWIS CARCINOMA; LOW DRUG DOSE; MOUSE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PLEURA EFFUSION; TREATMENT RESPONSE; TUMOR GROWTH; ANIMAL; C57BL MOUSE; DOWN REGULATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; EXPERIMENTAL NEOPLASM; GENE EXPRESSION REGULATION; INFLAMMATION; LUNG TUMOR; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); TUMOR CELL LINE;

MUS;

ANIMALS; BORONIC ACIDS; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; DRUG SCREENING ASSAYS, ANTITUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; INFLAMMATION; INFLAMMATION MEDIATORS; LUNG NEOPLASMS; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; NF-KAPPA B; PLEURAL EFFUSION, MALIGNANT; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES;

EID: 77949473596     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-9-56     Document Type: Article

References (31)

1. Antony VB, Loddenkemper R, Astoul P, Boutin C, Goldstraw P, Hott J, Rodriguez Panadero F, Sahn SA. Management of malignant pleural effusions. Eur Respir J 2001, 18:402-419. 10.1183/09031936.01.00225601, 11529302.
2. Antunes G, Neville E, Duffy J, Ali N, . Pleural Diseases Group, Standards of Care Committee, British Thoracic Society BTS guidelines for the management of malignant pleural effusions. Thorax 2003, 58(Suppl 2):ii29-38. 1766015, 12728148, Pleural Diseases Group, Standards of Care Committee, British Thoracic Society.
3. Sugiura S, Ando Y, Minami H, Ando M, Sakai S, Shimokata K. Prognostic value of pleural effusion in patients with non-small cell lung cancer. Clin Cancer Res 1997, 3:47-50.
4. Tremblay A. Tunnelled pleural catheters in malignant pleural effusion. Lancet 2007, 370:387. 10.1016/S0140-6736(07)61189-1, 17679012.
5. Viallat JR, Rey F, Astoul P, Boutin C. Thoracoscopic talc poudrage pleurodesis for malignant effusions. A review of 360 cases. Chest 1996, 110:1387-1393. 10.1378/chest.110.6.1387, 8989050.
6. Light RW. Talc for pleurodesis?. Chest 2002, 122:1506-1508. 10.1378/chest.122.5.1506, 12426241.
7. Maskell NA, Lee YC, Gleeson FV, Hedley EL, Pengelly G, Davies RJ. Randomized trials describing lung inflammation after pleurodesis with talc of varying particle size. Am J Respir Crit Care Med 2004, 170:377-382. 10.1164/rccm.200311-1579OC, 15142871.
8. Burgers JA, Kunst PW, Koolen MG, Willems LN, Burgers JS, Heuvel M. Pleural drainage and pleurodesis: implementation of guidelines in four hospitals. Eur Respir J 2008, 32:1321-1327. 10.1183/09031936.00165607, 18614555.
9. Yeh H-H, Lai W-W, Chen HHW, Liu H-S, Su W-C. Autocrine IL-6-induced Stat3 activation contributes to the pathogenesis of lung adenocarcinoma and malignant pleural effusion. Oncogene 2006, 25:4300-4309. 10.1038/sj.onc.1209464, 16518408.
10. Stathopoulos GT, Lee YCG. Experimental Models: Pleural diseases other than mesothelioma. Textbook of Pleural Diseases 2008, 169-186. London: Hodder Arnold, Light RW, Lee YCG, 2.
11. Yano S, Shinohara H, Herbst RS, Kuniyasu H, Bucana CD, Ellis LM, Fidler IJ. Production of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells. Am J Pathol 2000, 157:1893-1903. 1885766, 11106562.
12. Stathopoulos GT, Zhu Z, Everhart MB, Kalomenidis I, Lawson WE, Bilaceroglu S, Peterson TE, Mitchell D, Yull FE, Light RW, Blackwell TS. Nuclear factor-κB affects tumor progression in a mouse model of malignant pleural effusion. Am J Respir Cell Mol Biol 2006, 34:142-150. 10.1165/rcmb.2005-0130OC, 2644178, 16210694.
13. Stathopoulos GT, Sherrill TP, Han W, Sadikot RT, Polosukhin VV, Fingleton B, Yull FE, Blackwell TS. Use of bioluminescent imaging to investigate the role of nuclear factor-κB in experimental non-small cell lung cancer metastasis. Clin Exp Metastasis 2008, 25:43-51. 10.1007/s10585-007-9100-z, 18008176.
14. Stathopoulos GT, Kollintza A, Moschos C, Psallidas I, Sherrill TP, Pitsinos EN, Vassiliou S, Karatza M, Papiris SA, Graf D, Orphanidou D, Light RW, Roussos C, Blackwell TS, Kalomenidis I. Tumor necrosis factor-α promotes malignant pleural effusion. Cancer Res 2007, 67:9825-9834. 10.1158/0008-5472.CAN-07-1064, 17942913.
15. Stathopoulos GT, Psallidas I, Moustaki A, Moschos C, Kollintza A, Karabela S, Porfyridis I, Vassiliou S, Karatza M, Zhou Z, Joo M, Blackwell TS, Roussos C, Graf D, Kalomenidis I. A central role for tumor-derived monocyte chemoattractant Protein-1 in malignant pleural effusion. J Natl Cancer Inst 2008, 100:1464-1476. 10.1093/jnci/djn325, 18840818.
16. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E, Ben-Neriah Y. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 2004, 431:461-466. 10.1038/nature02924, 15329734.
17. Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, Kagnoff MF, Karin M. IKKβ links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004, 118:285-296. 10.1016/j.cell.2004.07.013, 15294155.
18. Stathopoulos GT, Sherrill TP, Cheng DS, Scoggins RM, Han W, Polosukhin VV, Connelly L, Yull FE, Fingleton B, Blackwell TS. Epithelial nuclear factor-κB activation promotes urethane-induced lung carcinogenesis. Proc Natl Acad Sci USA 2007, 104:18514-18519. 10.1073/pnas.0705316104, 2141808, 18000061.
19. Burke JR, Pattoli MA, Gregor KR, Brassil PJ, MacMaster JF, McIntyre KW, Yang X, Iotzova VS, Clarke W, Strnad J, Qiu Y, Zusi FC. BMS-345541 is a highly selective inhibitor of IκB kinase that binds at an allosteric site of the enzyme and blocks NF-κB-dependent transcription in mice. J Biol Chem 2003, 278:1450-6. 10.1074/jbc.M209677200, 12403772.
20. Sunwoo JB, Chen Z, Dong G, Yeh N, Crowl Bancroft C, Sausville E, Adams J, Elliott P, Van Waes C. Novel proteasome inhibitor PS-341 inhibits activation of NF-kB, cell survival, tumor growth and angiogenesis in squamous cell carcinoma. Clin Cancer Res 2001, 7:1419-1428.
21. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003, 348:2609-2617. 10.1056/NEJMoa030288, 12826635.
22. Rajkumar SV, Richardson PG, Hideshima T, Anderson KC. Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 2005, 23:630-639. 10.1200/JCO.2005.11.030, 15659509.
23. Teicher BA, Ara G, Herbst R, Palombella VJ, Adams J. The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 1999, 5:2638-2645.
24. Fanucchi MP, Fossella FV, Belt R, Natale R, Fidias P, Carbone DP, Govindan R, Raez LE, Robert F, Ribeiro M, Akerley W, Kelly K, Limentani SA, Crawford J, Reimers HJ, Axelrod R, Kashala O, Sheng S, Schiller JH. Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. J Clin Oncol 2006, 24:5025-5033. 10.1200/JCO.2006.06.1853, 17075122.
25. Davies AM, Chansky K, Lara PN, Gumerlock PH, Crowley J, Albain KS, Vogel SJ, Gandara DR, . Southwest Oncology Group Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339). J Thorac Oncol 2009, 4:87-92. 10.1097/JTO.0b013e3181915052, 19096312, Southwest Oncology Group.
26. Stathopoulos GT, Moschos C, Loutrari H, Kollintza A, Psallidas I, Karabela S, Magkouta S, Zhou Z, Papiris SA, Roussos C, Kalomenidis I. Zoledronic acid is effective against experimental malignant pleural effusion. Am J Respir Crit Care Med 2008, 178:50-59. 10.1164/rccm.200710-1513OC, 18388351.
27. Adams J, Stein R. Novel inhibitors of the proteasome and their therapeutic use in inflammation. Ann Rep Med Chem 1996, 31:279-288.
28. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V, Sobin L, . International Association for the Study of Lung Cancer International Staging Committee; Participating Institutions The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007, 2:706-714. 10.1097/JTO.0b013e31812f3c1a, 17762336, International Association for the Study of Lung Cancer International Staging Committee; Participating Institutions.
29. Hanahan D, Weinberg RA. The halmarks of cancer. Cell 2000, 100:57-70. 10.1016/S0092-8674(00)81683-9, 10647931.
30. Karin M. Inflammation and cancer: the long reach of Ras. Nat Med 2006, 11:20-21.
31. Dalmay T, Edwards DR. MicroRNAs and the hallmarks of cancer. Oncogene 2006, 25:6170-6175. 10.1038/sj.onc.1209911, 17028596.